1. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–619.
2. Jing ZC, Jiang X, Han ZY et al. Yang1 and J-L. Pu1. Iloprost for pulmonary vasodilator testing inidiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1354–60.
3. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. ERJ 2008; 31 (4): 881–901.
4. Olschewski H, Ghofrani HA et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132: 435–43.
5. Galie` N, Ussia G, Passarelli P et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A–62A.
6. Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356–65.
7. Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhalednitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000; 35: 176–82.
8. Hoeper MM, Lee SH, Voswinckel R et al. Complications ofright heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546–52.
9. Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820–4.
10. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010; 104: 731–40.
11. McLaughlin V, Oudiz R, Frost A. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257–63.
12. Hong-liang Z, Zhi-hong L et al. Acute responses to inhalation of Iloprost in patients with pulmonary hypertension. Chin Med J 2012; 125 (16): 2826–31.
13. Borges AC, Wensel R, Opitz C et al. Relationship between haemodynamics and morphology in pulmonary hypertension. A quantitative intravascular ultrasound study. Eur Heart J 1997; 18: 1988–94.
14. Berger RMF, Cromme-Dijkhuis AH, Van Vliet AM et al. Evaluation of the pulmonary vasculature and dynamics with intravascular ultrasound imaging in children and infants. Pediatr Res 1995; 38: 36–41.
15. Ivy D, Neish SR, Knudson O et al. Intravascular ultrasonic characteristics and vasoreactivity of the pulmonary vasculature in children with pulmonary hypertension. Am J Cardiol 1998; 81: 740–8.
16. Bressollette E, Dupuis J, Bonan R et al. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest 2001; 120: 80–91.
17. Galie N, Hoeper MM, Humbert M et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009 [Epub ahead of print] Eur Respir J 2009 [Epub ahead of print].
18. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273–7.
19. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–11.
20. Hoeper MM, Lee SH, Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546–52.
21. Paulus WJ, Tschope C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–50.
22. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76–81.
23. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–11.
24. Galie N, Ussia G, Passarelli P et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A–62A.

Н.М.Данилов, Т.В.Мартынюк, Е.А.Белятко, Ю.Г.Матчин, И.Е.Чазова

Институт клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава РФ, Москва